St. Joseph Cancer Center - Clinical Trials: Gastrointestinal
  

Colon:

  • CTSU E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin vs 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

  • CTSU N0147: A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer (Available to patients ages 18-69 only.)

Colorectal

  • CTSU C80405: A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Esophagus:

  • None Currently

Gastric:

  • None Currently

GIST:

  • SWOG 0502: A Phase III Randomized Study of Imatinib, with or without Bevacizumab (NSC-704865), in Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors

Neuroendocrine:

  • SWOG 0518:  Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha versus Depot Octreotide plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients

Pancreas:

  • None Currently

Rectal:

  • NSABP R-04: A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum

  • SWOG 0713: A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-operative Therapy of Rectal Cancer
     

For more information on the above clinical trials: Cheryl Patz, RN, OCN, CCRC, 360.715.4133

 

Return to previous page

Cancer Services

Cancer Committee

Cancer Program